AZN Stock Up 1% in Pre-market, AstraZeneca Vaccine Found to Be 79% Effective in US with No Safety Issues
AstraZeneca anticipates the vaccine to continue being shipped to different countries to combat the coronavirus spread.
AZN Stock Jumped 3%, WHO Approves AstraZeneca Coronavirus Vaccine for Emergency Use
Notably, the World Health Organization has approved two different versions of the AstraZeneca vaccine that were found out to be approximately 63% effective.
AstraZeneca Vaccine Appears Less Effective against COVID-19 in South Africa
At press time, AstraZeneca stock is at $50 in the pre-market trading, which shows a 0.54% increase over its previous close of $49.73.
AZN Stock Jumps 3% as UK Begins Rollout of Oxford-AstraZeneca COVID-19 Vaccine
The AstraZeneca (AZN) shares are up today with investors bearing the sentiment that the stock will witness an improved performance thanks to the obvious advantages the Oxford-AZN vaccine has over its rivals.
AZN Stock Up 4% in Pre-Market as AstraZeneca Vaccine Nears UK Approval
By
John K. Kumi
Pascal Soriot, the Chief Executive of AstraZeneca revealed that the vaccine is as effective as Pfizer and can be a strong protector against the new variant of the virus which is very contagious.
AstraZeneca Coronavirus Vaccine Candidate Can Be Ready by End of Year
AstraZeneca Q3 revenue was in line with the expected forecast at $6.6 billion.
AstraZeneca to Release Trial Data for Covid-19 Vaccine by Year End
Currently, AstraZeneca vaccine trials are in the late-stages, involving about 23,000 participants. The participants span across the UK, U.S., South Africa, and Brazil.
COVID-19 Vaccine Volunteer in Brazil’s AstraZeneca Trial Dies, AZN Stock Plummets 1%
By
Darya Rudz
It is unclear whether the volunteer took the vaccine dose or was in a placebo group. AstraZeneca has not provided much information but said they followed all required review processes.
AstraZeneca May Resume COVID-19 Vaccine Trial in U.S. This Week
By
Darya Rudz
As the draft of a form letter to UK AstraZeneca vaccine trial participants states, FDA “has come to the same conclusion as the other drug regulators including the MHRA” and approved further vaccine testing.
AZN Stock Up 1%, AstraZeneca Gets $486M from U.S. for 100K COVID-19 Vaccine Doses
Although the vaccine by AstraZeneca has not been globally approved, it was used in the treatment of U.S. President Donald Trump.
AZN Stock Slightly Down, AstraZeneca Resumes Vaccine Trials in Japan, in Talks with U.S. Authorities
AstraZeneca’s clinical trials for the vaccine were halted in July after one of the participants complained of neurological disorder.
AZN Stock Down 0.6%, AstraZeneca Receives Partial Immunity from EU in Vaccine Deal
By
Tolu Ajiboye
AstraZeneca has received partial immunity from the EU in a vaccine deal. The EU has already paid €336 million at €2.5 per dose.
Pharmaceutical Giant AstraZeneca Resumes Clinical Trials for COVID-19 Vaccine, AZN Stock Slightly Up
In partnership with U.K.’s Oxford University, AstraZeneca said that it will resume the phase three clinical trial for its COVID-19 vaccine contender AZD1222 since it got an approval from UK’s Medicines Health Regulatory Authority.
AstraZeneca Paused COVID-19 Vaccine Trial as It Caused Unexplained Side Effect
By
Darya Rudz
The Phase 3 trial started on August 31 and enrolled about 30,000 participants at 80 locations. Now it is unclear how long the clinical hold will last. But it is obvious that other pharma companies will have to review their safety measures as well.
AZN Shows Strong H1 Performance as AstraZeneca Advances COVID-19 Vaccine Clinical Trials
With the company’s ongoing late-stage clinical trials and its impressive H1 performance results, AstraZeneca (AZN) stock jumped in the pre-market.